Evidence map›Paper›PMID 33580212›Full record

ArticleThe Journal of antibiotics2021

Identification of a bacteria-produced benzisoxazole with antibiotic activity against multi-drug resistant Acinetobacter baumannii.

Robert W Deering, Kristen E Whalen, Ivan Alvarez, Kathryn Daffinee, Maya Beganovic, Kerry L LaPlante, Shreya Kishore, Sijing Zhao, Brent Cezairliyan, Shen Yu and 3 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of antibiotics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.8field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 1 country.

Robert W Deering *Department of Biomedical and Pharmaceutical Sciences, College of Pharmacy, University of Rhode Island, Kingston, RI, USA.
Kristen E Whalen *Department of Biology, Haverford College, Haverford, PA, USA. kwhalen1@haverford.edu.ORCID http://orcid.org/0000-0003-2116-0524
Ivan AlvarezDepartment of Biomedical and Pharmaceutical Sciences, College of Pharmacy, University of Rhode Island, Kingston, RI, USA.
Kathryn DaffineeDepartment of Pharmacy Practice, College of Pharmacy, University of Rhode Island, Kingston, RI, USA.
Maya BeganovicDepartment of Pharmacy Practice, College of Pharmacy, University of Rhode Island, Kingston, RI, USA.
Kerry L LaPlanteDepartment of Pharmacy Practice, College of Pharmacy, University of Rhode Island, Kingston, RI, USA.
Shreya KishoreDepartment of Biology, Haverford College, Haverford, PA, USA.
Sijing ZhaoDepartment of Biology, Haverford College, Haverford, PA, USA.
Brent CezairliyanOctagon Therapeutics, Inc., Cambridge, MA, USA.
Shen YuOctagon Therapeutics, Inc., Cambridge, MA, USA.
Margaret RosarioDepartment of Biomedical and Pharmaceutical Sciences, College of Pharmacy, University of Rhode Island, Kingston, RI, USA.
Tracy J MincerWilkes Honors College and Harbor Branch Oceanographic Institute, Florida Atlantic University, Boca Raton, FL, USA. tmincer@fau.edu.
David C RowleyDepartment of Biomedical and Pharmaceutical Sciences, College of Pharmacy, University of Rhode Island, Kingston, RI, USA. drowley@uri.edu.ORCID http://orcid.org/0000-0001-7808-1312
University of Rhode Island · USHaverford College · USIo Therapeutics (United States) · USFlorida Atlantic University · US

Funding

Training CoreP20GM103430 · NIGMS · UNIVERSITY OF RHODE ISLAND · PI Bongsup P Cho · 2012 to 2026
$63.6M
Discovery and development of RND pump inhibitors from marine microbial sourcesR21AI119311 · NIAID · WOODS HOLE OCEANOGRAPHIC INSTITUTION · PI MINCER, TRACY JOHN · 2015 to 2015
$341k
NIAID NIH HHS R21 AI119311NIGMS NIH HHS P20 GM103430
6 · The paper itself

Abstract

The emergence of multi-drug resistant pathogenic bacteria represents a serious and growing threat to national healthcare systems. Most pressing is an immediate need for the development of novel antibacterial agents to treat Gram-negative multi-drug resistant infections, including the opportunistic, hospital-derived pathogen, Acinetobacter baumannii. Herein we report a naturally occurring 1,2-benzisoxazole with minimum inhibitory concentrations as low as 6.25 μg ml

Indexed as

Acinetobacter baumanniiAnti-Bacterial AgentsBacterial ProteinsBradyrhizobiumDrug AntagonismDrug Resistance, Multiple, BacterialEnzyme InhibitorsMicrobial Sensitivity TestsMolecular Docking SimulationMolecular StructureOxo-Acid-LyasesParabensPseudomonas aeruginosa4-hydroxybenzoic acidAnti-Bacterial AgentsBacterial Proteinschorismate pyruvate lyaseEnzyme InhibitorsOxo-Acid-LyasesParabens

Identifiers

PMID33580212
PMCPMC7879144
OpenAlexW3128507935

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.